# Advisor Review - Advisor 1/3

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-29T00:24:16.066504
**Response ID:** resp_0d018cb21a1612d500697a99b495148196ba5c0f6e93754ef4
**Tokens:** 18805 in / 5656 out
**Response SHA256:** f5dda3e6b32e53d2

---

No fatal errors found in the categories you specified. I checked:

- **Data–design alignment:** Treatment adoption years (2022, 2023) are within the **CPS-FSS 2022–2024** survey-year coverage; your identifying sample restriction to **2023 adopters + never-treated** is consistent with the lack of within-state variation for 2022 adopters under state FE. Post-treatment observations exist for the 2023 cohort (survey years 2023 and 2024). Treatment cohort definitions are consistent across Table 1 and the regression samples (with the explicit restriction noted in Table 3/5 notes).

- **Regression sanity:** All reported coefficients/SEs are in plausible ranges for binary outcomes measured in percentage points. No impossible values (NA/Inf/negative SEs/R² out of bounds) appear. No tables show exploding SEs indicative of absorbed regressors/collinearity artifacts.

- **Completeness:** Regression tables report **N**, clustering level, and uncertainty (SEs and/or CIs). Figures/tables referenced in the provided excerpt appear to exist (Figures 1–5; Tables 1–6), and analyses described in the results section are actually shown (TWFE, C&S, DDD, randomization inference).

- **Internal consistency:** Key numbers quoted in the abstract match the tables (e.g., TWFE 0.047 with SE 0.020; DDD −0.008 with SE 0.013 and CI [−0.034, 0.018]). Sample definitions and cohort counts are consistent (4 treated states in the 2023 cohort; 46 state/DC units; 138 state-year cells for 46×3).

ADVISOR VERDICT: PASS